Next Quarterly Earnings
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Camurus is a Swedish pharmaceutical company dedicated to developing and commercializing innovative specialty medicines. The company leverages advanced drug development technologies to enhance therapies for patients with severe and rare diseases. Camurus conducts intensive research and development (R&D) to address unmet medical needs across various therapeutic areas, aiming for a sustained improvement in patients' lives.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Camurus is scheduled to report its next quarterly earnings on 11/05/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Camurus last reported quarterly earnings on 7/15/2026 (Q2 2026). Earnings per share (EPS) came in at 4.07 SEK.
Across its last 3 earnings reports, Camurus stock moved by ±12.2% on average the following day. The largest reaction was -24% on 02/12/2026; 0 of 3 reactions were positive.
Camurus has beaten analyst EPS estimates in 2 of its last 5 evaluated quarters (beat rate: 40%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 3 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.